Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Theratechnologies Inc
T.TH
Alternate Symbol(s):
THTX
Healthcare
Biotechnology
Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs...
in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
TSX:TH - Post Discussion
Theratechnologies Inc
> Case-finding strategies in non-alcoholic fatty liver disease
New Post
View:
Discussion
List
(210)
•••
scarlet1967
X
View Profile
View Bullboard History
Post by
scarlet1967
on Apr 03, 2021 11:19am
Case-finding strategies in non-alcoholic fatty liver disease
Well the summary says it all..
“Among the large population of patients with non-alcoholic fatty liver disease (NAFLD), identifying those with advanced disease remains challenging. Many patients are diagnosed late, following the development of liver-related complications, leading to poor clinical outcomes. Accumulating evidence suggests that using non-invasive tests for liver fibrosis in patients with metabolic risk factors improves the detection of patients in need of specialised management and is cost-effective. Because of the vast number of patients requiring evaluation, the active participation of general practitioners and physicians who manage patients with metabolic disorders, such as diabetologists, is crucial; this calls for the increased awareness of NAFLD beyond liver clinics. Non-invasive case-finding strategies will need to be further validated and generalised for upcoming drug therapies to have the required impact on the worldwide burden of NAFLD.”
https://www.jhep-reports.eu/article/S2589-5559(20)30153-1/fulltext
(28)
•••
Wino115
X
View Profile
View Bullboard History
Comment by
Wino115
on Apr 03, 2021 1:14pm
Whenever there's a barrier between a disease and the payors unwillingness to blindly pay for treatment, science steps in and creates innovative tests. This will be the same. Payors/Insurers will want something more failproof than a hunch and large wasteband in order to start treatement. Less expensive testing can be done early to detect it before it gets to the worst case
...more
(210)
•••
scarlet1967
X
View Profile
View Bullboard History
Comment by
scarlet1967
on Apr 03, 2021 1:44pm
Quite frankly if the science backs up set of accurate diagnostic sets which are more cost effective and less invasive it's a win win situation for all parties, patients get detected earlier thus less advanced symptoms, less pressure to the healthcare thus more resources to deal with othe conditions and less costs to payors as they don't need to cover lengthy and extensive treatment for
...more
(28)
•••
Wino115
X
View Profile
View Bullboard History
Comment by
Wino115
on Apr 03, 2021 3:34pm
The negative to it all is that if you can develop a test with high accuracy and predictability that your liver is at the NAFLD or early NASH stage, likey the intervention would be diet, exercise and vitamin E (or whatever it is they tell you to take). That will work for plenty of people and lower the percentage that get in to the NASH or advanced NASH stages. That would be a far better
...more
(210)
•••
scarlet1967
X
View Profile
View Bullboard History
Comment by
scarlet1967
on Apr 03, 2021 3:43pm
Hopefully early detection and prevention would work for as many as possible but from my own experience I know to convince people changing their habits it's easier said than done.
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Do you want to stay ahead of the markets? See how DealRoom can help.
Growth Rocket 2025 – Why dynaCERT is in the Spotlight